Recruiting studies: Pancreatic Ductal Adenocarcinoma Mpdac

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
Phase 1/Phase 2 · 5 location(s) · Clinica Universidad de Navarra, Universidad de Navarra · NCT07284277 A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastati
Phase 1/Phase 2 · 1 location(s) · Theriva Biologics SL · NCT07701486 Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Phase 2 · 1 location(s) · University of California, San Diego · NCT06790602 Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Che
Phase 3 · 71 location(s) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Develop · NCT07165951 Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Duc
Phase N/A · 9 location(s) · Hellenic Cooperative Oncology Group · NCT07723261 Immunoparalysis After Pancreaticoduodenectomy
Phase N/A · 4 location(s) · Hospices Civils de Lyon · NCT07144917 A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction A
Phase 1 · 3 location(s) · Dong-A ST Co., Ltd. · NCT07481357

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.